Targeting Leptomeningeal Brain Tumors With CAR T Therapy
Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio, discussed upcoming research on MB-101 cell therapy.
The Need for New Therapies in DLBC Lymphoma: Gilles Salles, MD
The lymphoma service chief at Memorial Sloan Kettering Cancer Center discussed the need for new therapies to treat diffuse large B-cell lymphoma.
CAR T and Other Approaches for Patients with R/R DLBC Lymphoma
Loretta Nastoupil, MD, and John Burke, MD, discussed treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Improving Gene and Cell Therapy Conditioning Regimens With JSP191
The executive vice president of research and development at Jasper Therapeutics discussed how JSP191 is designed to be better-tolerated than current conditioning regimens.
Novel Treatments for Hematologic Malignancies: Julie Vose, MD
The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed novel treatment options for patients with hematologic malignancies.
CG0070: A Genetically Modified Immunotherapy for Non-Muscle Invasive Bladder Cancer
The first patient in CG Oncology's phase 2 study of CG0070 was dosed in December 2020.
Benefits of CAR T Therapy in Follicular Lymphoma: Julie Vose, MD
The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.
Advantages of Manufacturing Cell Therapies In-House
The chief technology and chief executive officer of Mustang Bio discussed the company’s integrated approach to drug development.
DLBCL Second-Line Therapy Recommendations
Experts discussed their recommendations for second-line treatment options for patients with DLBCL.
Unique Challenges With Gene Therapy in Duchenne Muscular Dystrophy
The co-founder, president, and chief executive officer of Solid Biosciences, whose own son has DMD, discussed challenges in developing gene therapies for DMD.
Exploring Advanced Approaches for Pain Relief
The chief executive officer and co-founder of Flexion Therapeutics discussed the company’s pain-focused pipeline, which includes a gene therapy that targets inflammation.
Novel Therapies in Development for Dravet Syndrome
Joseph Sullivan, MD, and Elaine C. Wirrell, MD, discuss new developments for the treatment of Dravet syndrome beyond seizure control including gene editing and therapy.
Improving Efficiency in CAR T Cell Therapy Production
The chief technology officer of Mustang Bio discussed the company’s approach and future plans in CAR T production.
Ide-Cel Shows Durable Response in R/R Multiple Myeloma: Larry D. Anderson, Jr, MD, PhD
The hematologist/oncologist from the Harold C. Simmons Comprehensive Cancer Center discussed the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.
CD20-Targeted Gene Therapy
Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio discussed the company’s lead and second program.
Orca-T for Graft-Versus-Host Disease: Mehrdad Abedi, MD
The professor of medicine at the UC Davis Comprehensive Cancer Center discussed Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.
Challenges in Conducting Research in DMD
The co-founder, president, and chief executive officer of Solid Biosciences, whose own son has DMD, discussed some challenges the company is facing.
Novel Therapies in Heavily Pretreated Multiple Myeloma: Omar Nadeem, MD
The physician from the Dana-Farber Cancer Institute discussed the uptake of novel therapies in heavily pretreated multiple myeloma.
Investigating CAR T in Lymphoma, Leukemia, and Solid Tumors
The president, chief executive officer, and director of Mustang Bio discussed the company’s pipeline.
Future Research With Car T-Cell Therapy in Multiple Myeloma: Adam Sperling, MD, PhD
The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed future research with CAR T-cell therapy in multiple myeloma.
Making Antigen-Presenting Cells With Cell Squeeze Technology
The founder and chief executive officer of SQZ Biotech discussed the potential of their APC platform to treat a variety of tumors.
Investigating Cell Therapy in Multiple Myeloma: Adam Sperling, MD, PhD
The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed reasons to evaluate cellular therapy in multiple myeloma.
Integrating Ide-Cel Into Pretreated Multiple Myeloma Regimens: Shaji Kumar, MD
The hematologist from Mayo Clinic discussed the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.
Looking Forward in Relapsed/Refractory Multiple Myeloma Treatments
James Hoffman, MD, leads a discussion about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
Mitigating Adverse Events in CAR T-Cell Therapy: Mounzer Agha, MD
The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed strategies to manage AEs associated with CAR T therapy.
Clinical Implications of Tisagenlecleucel in B-ALL Treatment: Michael R. Grunwald, MD, FACP
The hematologic oncologist at the Levine Cancer Institute discussed the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.
The Potential of Gene Transfer Therapy in SMA
John Brandsema, MD, discusses gene transfer for the management of SMA and the recent approval of onasemnogene abeparvovec-xioi.
The Potential of CAR T-Cell Therapy in Adult ALL
Eunice Wang, MD, and Bijal Shah, MD, MS, discussed unmet needs for adult patients with relapsed/refractory ALL and reflect on the current treatment landscape.
Advantages of Cell Squeeze Technology Over Electroporation and Viral Transfection
The founder and chief executive officer of SQZ Biotech discussed the development and advantages of their proprietary Cell Squeeze technology in creating cell therapies.
The Use of Clinical Endpoints in the ZUMA-3 Trial
Bijal Shah, MD, MS, and Eunice Wang, MD, discussed the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy.
